Platelet Rich Plasma vs Corticosteroids for Hip Osteoarthritis

Overseen By Martin Gesheff, DHSc

Age: 18+

Sex: Any

Trial Phase: Phase 4

Sponsor: LifeBridge Health

Must not be taking: Opioids, Investigational drugs

Disqualifiers: Chronic pain, Diabetes, Pregnancy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 6

Duration: 6 weeks

54 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests two treatments, platelet-rich plasma (PRP) and corticosteroids, to determine which better reduces pain and improves function in people with hip osteoarthritis. Hip osteoarthritis causes joint pain and stiffness, making daily activities challenging. The trial seeks participants diagnosed with moderate hip osteoarthritis who are eligible for a hip injection. As a Phase 4 trial, the treatments have already received FDA approval and proven effective, aiming to understand how they benefit more patients.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, if you are taking opioids or have had recent injections in the hip, you may not be eligible to participate.

What is the safety track record for these treatments?

Earlier studies have found platelet-rich plasma (PRP) injections to be safe and effective for treating hip osteoarthritis (OA). Research shows that PRP can improve joint function and reduce pain, maintaining a high level of safety. Most patients tolerate PRP well, with only a few side effects reported.

Corticosteroids, approved by the FDA for treating inflammation, are also commonly used for hip OA. They are generally well-tolerated, though some patients may experience side effects like temporary pain at the injection site or a rise in blood sugar levels.

Both treatments have evidence supporting their safe use in managing hip OA. Participants should consider how each option aligns with their personal health needs when deciding to join the study. ^{1 2 3 4 5}

Why are researchers enthusiastic about this study treatment?

Researchers are excited about using Platelet Rich Plasma (PRP) for hip osteoarthritis because it offers a natural alternative to traditional treatments like corticosteroids. Unlike corticosteroids, which primarily reduce inflammation, PRP uses a concentration of your own blood platelets to potentially heal damaged tissues and improve joint function. The possibility of promoting tissue regeneration makes PRP a promising option for long-term relief and recovery, setting it apart from standard anti-inflammatory treatments.

What evidence suggests that this trial's treatments could be effective for hip osteoarthritis?

This trial will compare the effectiveness of platelet-rich plasma (PRP) injections with corticosteroid injections for treating hip osteoarthritis. Research has shown that both PRP and corticosteroid injections are effective for this condition. Studies have found that PRP injections can significantly reduce pain and improve hip function, often outperforming another treatment called hyaluronic acid. Patients receiving PRP often experience less pain and improved joint movement. Corticosteroid injections are already known for quickly reducing inflammation and pain in osteoarthritis. This trial aims to determine which treatment more effectively reduces symptoms, but current evidence supports both options as effective for managing hip osteoarthritis. ^{4 6 7 8 9}

Are You a Good Fit for This Trial?

This trial is for individuals with hip osteoarthritis who are experiencing pain and functional issues. Specific eligibility criteria details were not provided, so it's important to contact the study organizers for more information on who can participate.

Inclusion Criteria

I am between 21 and 80 years old.

I am recommended to get a hip injection for my hip arthritis symptoms.

Provision of signed and dated informed consent form

Exclusion Criteria

I haven't had injections in my hip in the last 3 months.

I have a skin infection over the area of interest.

Allergy to any potential ingredients or medications utilized in any of the two groups

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either a 5 mL injection of corticosteroid or approximately 10 mL of autologous PRP for the treatment of hip osteoarthritis

6 weeks

3 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, with assessments at baseline, six weeks, and three months

3 months

3 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

• Corticosteroid
• Platelet Rich Plasma

Trial Overview The trial is comparing two treatments: platelet rich plasma (PRP) injections versus corticosteroid injections in patients with hip osteoarthritis. It aims to see which treatment better reduces pain and improves function according to patient reports.

How Is the Trial Designed?

Group I: Autologous Platelet Rich Plasma Experimental Treatment 1 Intervention

\~Injection of approximately 10 mL autologous PRP Magellan Autologous Concentration System, ISTO Biologics

Group II: Corticosteroid Active Control 1 Intervention

5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)

Who Is Running the Clinical Trial?

LifeBridge Health

Lead Sponsor

Trials

32

Recruited

4,500+

Hip Society

Collaborator

Trials

1

Recruited

50+

Published Research Related to This Trial

In a study of 42 patients with early knee osteoarthrosis, treatment with platelet rich plasma (PRP) resulted in a significant clinical improvement, with KOOS scores increasing from 30.1 to 48.2 points, indicating a 60% improvement over 6 months.

While both PRP and paracetamol treatments did not show significant differences in inflammatory markers IL-1β and TNF-a, PRP treatment led to a notable increase in TGF-β1 levels, which correlated with the observed clinical benefits.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Platelet rich plasma versus oral paracetamol for the treatment of early knee osteoarthritis. Preliminary study]. Acosta-Olivo, C., Esponda-Colmenares, F., Vilchez-Cavazos, F., et al.[2018]

Intra-articular injections of platelet-rich plasma (PRP) significantly reduced pain in patients with hip osteoarthritis (OA) compared to hyaluronic acid (HA) and the combination of PRP and HA, with the PRP group showing the lowest pain scores at 6 months.

The study, involving 111 patients, demonstrated that PRP injections led to meaningful improvements in quality of life and functional recovery, with no significant side effects reported, making it a safe and effective treatment option for hip OA.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Ultrasound-Guided Injection of Platelet-Rich Plasma and Hyaluronic Acid, Separately and in Combination, for Hip Osteoarthritis: A Randomized Controlled Study. Dallari, D., Stagni, C., Rani, N., et al.[2018]

Corticosteroids are found to provide the best short-term relief for hip osteoarthritis when used in intra-articular injections, while platelet-rich plasma may offer more benefits in the mid-term, although results can vary.

There is a need for more rigorous studies to better evaluate the effectiveness of different adjuvants, especially biologics, and to establish clear guidelines for their use in injection therapy for osteoarthritis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Editorial Commentary: Intra-articular Injection for Osteoarthritis-Is It Hip or Not? Gerhardt, MB., Robinson, S.[2020]

In a study involving 62 participants with knee osteoarthritis, neither platelet-rich plasma (PRP) nor plasma showed significant improvement in pain or function compared to a saline placebo over 24 weeks.

The PRP group experienced a higher rate of mild adverse events, with 65% reporting increased pain, indicating that while PRP is a minimally invasive treatment, it may not be safer or more effective than placebo.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy of platelet-rich plasma and plasma for symptomatic treatment of knee osteoarthritis: a double-blinded placebo-controlled randomized clinical trial. Dório, M., Pereira, RMR., Luz, AGB., et al.[2022]

Ultrasound-guided platelet-rich plasma (PRP) injections for hip osteoarthritis were found to be well tolerated and led to significant pain reduction and functional improvement in patients, with benefits lasting up to 12 months.

The review analyzed three high-quality randomized clinical trials involving 115 patients, suggesting that PRP injections could be an effective treatment option, although larger studies with placebo controls are needed to confirm these findings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The use of ultrasound-guided platelet-rich plasma injections in the treatment of hip osteoarthritis: a systematic review of the literature. Ali, M., Mohamed, A., Ahmed, HE., et al.[2020]

Intra-articular treatment with platelet-rich plasma (PRP) showed a significant reduction in pain for patients with hip osteoarthritis at 4 weeks, but this effect did not last by 16 weeks, indicating a short-term benefit.

In contrast, viscosupplementation with hyaluronic acid (HA) demonstrated a sustained reduction in pain from baseline to 16 weeks, suggesting it may be more effective for long-term management of hip osteoarthritis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Intra-articular hyaluronic acid vs platelet-rich plasma in the treatment of hip osteoarthritis. Di Sante, L., Villani, C., Santilli, V., et al.[2022]

A one-time injection of platelet-rich plasma (PRP) significantly reduced knee pain and improved daily living activities and quality of life in patients with osteoarthritis compared to corticosteroid injections, based on a study of 41 participants over 6 months.

PRP treatment showed better outcomes in pain relief and functional improvement (measured by the 20-Meter-Walk Test) than corticosteroids, although neither treatment affected the range of motion in the knee.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effect of single injection of platelet-rich plasma in comparison with corticosteroid on knee osteoarthritis: a double-blind randomized clinical trial. Forogh, B., Mianehsaz, E., Shoaee, S., et al.[2022]

A systematic review of six studies involving 408 patients found that both platelet-rich plasma (PRP) and hyaluronic acid (HA) injections provide similar short-term clinical benefits for treating hip osteoarthritis, with no significant differences in pain and function scores after treatment.

The analysis included patients with a mean age of around 60 years and a follow-up period of approximately 12 months, indicating that both treatments are effective options for managing symptoms of hip OA.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Platelet-Rich Plasma Versus Hyaluronic Acid for Hip Osteoarthritis Yields Similarly Beneficial Short-Term Clinical Outcomes: A Systematic Review and Meta-analysis of Level I and II Randomized Controlled Trials. Belk, JW., Houck, DA., Littlefield, CP., et al.[2022]

In a study of 50 patients with knee osteoarthritis, platelet-rich plasma (PRP) therapy showed a significant reduction in pain and improvement in function over 180 days compared to standard corticosteroid treatment (triamcinolone).

PRP therapy not only demonstrated effectiveness in alleviating pain and enhancing function but also had fewer side effects and provided longer-lasting benefits than corticosteroids, making it a promising alternative for treating knee osteoarthritis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparative Effect between Infiltration of Platelet-rich Plasma and the Use of Corticosteroids in the Treatment of Knee Osteoarthritis: A Prospective and Randomized Clinical Trial. Freire, MRM., da Silva, PMC., Azevedo, AR., et al.[2020]

In a study involving 80 patients with early osteoarthritis of the hip, both autologous platelet-rich plasma (PRP) and hyaluronic acid (HA) injections led to significant improvements in symptoms at 6 and 12 months, indicating both treatments are effective.

However, PRP did not demonstrate superior efficacy compared to HA, suggesting that PRP should not be considered a first-line treatment option for this condition.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Treatment of Early Hip Osteoarthritis: Ultrasound-Guided Platelet Rich Plasma versus Hyaluronic Acid Injections in a Randomized Clinical Trial. Doria, C., Mosele, GR., Caggiari, G., et al.[2020]

Corticosteroid injections effectively modulate inflammation and maintain synovial homeostasis in shoulder pain, as shown by their regulation of pro-inflammatory and anti-inflammatory cytokines.

When combined with platelet-rich plasma (PRP), corticosteroids enhance the regulation of certain inflammatory markers without interfering with the corticosteroid's effects, suggesting a synergistic benefit in treating inflammation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effects of corticosteroids and platelet-rich plasma on synoviocytes in IL-1ß-induced inflammatory condition. Yea, JH., Shin, S., Yoon, KS., et al.[2022]

In a review of three studies involving 363 hips, the use of platelet-rich plasma (PRP) after hip arthroscopy did not significantly improve postoperative pain or functional outcomes compared to control groups.

Although two of the studies showed some favor towards PRP treatment, overall results indicated that PRP may not provide the expected benefits in clinical outcomes following hip arthroscopy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Does Platelet-rich Plasma Augmentation Following Hip Arthroscopy Improve Outcomes: A Systematic Review. Ali, M., Benjamin, B., Jain, N., et al.[2020]

In a study of 40 patients with mild to moderate knee osteoarthritis, both platelet-rich plasma (PRP) and corticosteroid (CS) injections were found to be safe and effective for short-term pain relief and improved knee function, with no serious adverse effects reported.

However, PRP showed statistically significant improvements in pain and function compared to CS at the 15-week mark and continued to outperform CS at the 1-year follow-up, suggesting better long-term benefits of PRP for osteoarthritis treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Intra-articular platelet-rich plasma vs corticosteroids in the treatment of moderate knee osteoarthritis: a single-center prospective randomized controlled study with a 1-year follow up. Elksniņš-Finogejevs, A., Vidal, L., Peredistijs, A.[2021]

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC11488654/

Efficacy of Platelet-Rich Plasma Intra-articular Injections in Hip ... The study concluded that L-PRP injections significantly improved clinical outcomes in hip OA patients, proving more effective than HA alone or ...

2. academic.oup.com academic.oup.com/jhps/advance-article/doi/10.1093/jhps/hnaf008/8058728

Effectiveness of platelet-rich plasma in pain management of ... The study finds that PRP treatment is at least as effective as HA treatment in reducing hip pain for OA secondary to DDH.

3. sportsmed.org sportsmed.org/membership/sports-medicine-update/spring-2024/platelet-rich-plasma-for-osteoarthritis-in-2024

Platelet-Rich Plasma for Osteoarthritis in 2024 – More Hype A statistically significant improvement in patient-reported outcome scores was demonstrated with PRP over HA, while LP-PRP was associated with significantly ...

4. cureus.com cureus.com/articles/304833-efficacy-and-safety-of-platelet-rich-plasma-prp-intra-articular-injections-in-hip-osteoarthritis-a-systematic-review-of-randomized-clinical-trials

Efficacy and Safety of Platelet-Rich Plasma (PRP) Intra ... In conclusion, PRP injections appear to be a safe and effective treatment option for managing hip OA, with favorable outcomes compared to ...

5. sciencedirect.com sciencedirect.com/science/article/pii/S1743919118306770

Platelet rich plasma versus hyaluronic acid in patients with ... The present meta-analysis indicated that PRP was associated with a significant reduction of VAS score at 2 months compared with HA. However, it did not show ...

6. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/39569300/

Efficacy and Safety of Platelet-Rich Plasma (PRP) Intra ... In conclusion, PRP injections appear to be a safe and effective treatment option for managing hip OA, with favorable outcomes compared to ...

7. frontiersin.org frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1204144/full

Efficacy and safety of platelet-rich plasma injections for the ... In addition, PRP injection therapy can effectively improve the functional activity of OA patients and has a high level of safety for clinical applications. Data ...

8. hca.wa.gov hca.wa.gov/assets/program/HA-PRP-final-evidence-report.pdf

HA and PRP for Knee and Hip OA: Final evidence report This technology assessment report is based on research conducted by a contracted technology assessment center, with updates as contracted by ...

9. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC11371981/

Platelet-Rich Plasma for Knee and Hip Osteoarthritis Pain More than half (51.7%) of the clinical outcomes demonstrated significantly greater improvement with PRP versus HA. Additionally, 81.0% of all ...